Minimal Residual Disease--Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 10, p. 604, doi. 10.46883/2022.25920976
- By:
- Publication type:
- Article
Works matching IS 08909091 AND DT 2022 AND VI 36 AND IP 10
Results: 6
1
2
Investigating the Use of Circulating Tumor DNA in Early-Stage Colon Cancer.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 10, p. 620, doi. 10.46883/2022.25920977
- By:
- Publication type:
- Article
3
Antibody-Drug Conjugates in Gynecological Cancer: Setting the Stage.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 10, p. 632
- By:
- Publication type:
- Article
4
Circulating Tumor DNA as a Marker of Minimal Residual Disease.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 10, p. 600, doi. 10.46883/2022.25920975
- By:
- Publication type:
- Article
5
Paolo Tarantino, MD, Spotlights Treatment Trends for Breast Cancer Awareness Month.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 10, p. 592
- By:
- Publication type:
- Article
6
You Can Help Set New Paradigms Involving ctDNA.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 10, p. 591
- By:
- Publication type:
- Article